Biotechnology Cambridge, Massachusetts-based biotech Pyxis Oncology has entered into a worldwide license agreement with pharma giant Pfizer for the development and commercialization of two antibody-drug conjugate (ADC) candidates and a license to Pfizer’s ADC technology platform, enabling expansion of its ADC portfolio and further strengthening its developmental capabilities. 18 March 2021